The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

Sep. 10, 2019
Applicant:

Graybug Vision, Inc., Redwood City, CA (US);

Inventors:

Yun Yu, Baltimore, MD (US);

Joshua Kays, Baltimore, MD (US);

Ming Yang, Lutherville-Timonium, MD (US);

Jeffrey L. Cleland, San Carlos, CA (US);

Assignee:

Graybug Vision, Inc., Redwood City, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/50 (2006.01); A61K 9/16 (2006.01); A61K 31/5377 (2006.01); A61P 27/02 (2006.01); A61K 31/382 (2006.01); A61P 27/06 (2006.01); A61K 9/00 (2006.01); A61K 31/404 (2006.01); A61K 47/10 (2017.01); A61K 31/542 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5089 (2013.01); A61K 9/0048 (2013.01); A61K 9/1641 (2013.01); A61K 9/1647 (2013.01); A61K 9/5026 (2013.01); A61K 9/5031 (2013.01); A61K 31/382 (2013.01); A61K 31/404 (2013.01); A61K 31/5377 (2013.01); A61K 31/542 (2013.01); A61K 47/10 (2013.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01); A61K 9/0019 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01);
Abstract

The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.


Find Patent Forward Citations

Loading…